Chief executive officer
Bryan F. Cox
Dr. Cox is currently President of CoPharm Global Consulting, a boutique consultancy focused on providing guidance for biotechs and due diligence teams as they determine the best path forward from early discovery to first-in-man studies. Three of those projects have resulted in compounds obtaining US FDA Regulatory Approval: delafloxacin (Baxalta® - NDA), amantadine (Gocovri® - 505b2), and angiotensin II (Giapreza® - NDA/505b2 hybrid).
Prior to CoPharm Global, he was Director of Integrative Pharmacology at Abbott/Abbvie - responsible for both lead optimization and IND-enabling studies. In parallel, he served as Head of Renal Discovery.
He has (co-) authored/approved over 250 documents for Regulatory submission and participated in the advancement of over 60 compounds to Phase I clinical trials. Dr. Cox has published more than 100 papers in peer-reviewed journals and has twice been elected to Council for the American Society of Pharmacology and Experimental Therapeutics.
Dr. Cox was a charter member of the technical assessment team for Abbott BioVentures and spent over 20 years serving on due diligence teams – including fenofibrate (Tricor®) and elagolix (Orilissa®).
Prior to joining Abbott, Dr. Cox was with Rhone Poulenc Rorer. He received his PhD in Pharmacology from the University of Iowa and is currently an adjunct Professor of Pharmacology at the University of Iowa, College of Medicine.
Chief Development officer
Jim Stolzenbach
Dr. Stolzenbach has extensive pharmaceutical industry Research & Development experience. Jim previously served as Vice President for Renal and Immunology Therapeutic Development at Abbvie. He held senior leadership roles with Monsanto and Pharmacia including Vice President for Cardiovascular and Metabolic Product Development.
Dr. Stolzenbach has led global projects for both small molecule and biologic programs ranging from proof of concept trials to large Phase 3 trials designed for regulatory approval. During the course of his career, Jim co-authored over 30 publications in refereed journals with numerous abstracts for presentation.
Dr. Stolzenbach is a practiced entrepreneur serving as President of Jim Stolzenbach Consulting, LLC.
Dr. Stolzenbach has a Bachelor’s degree in Science from the University of Connecticut, a Master’s degree from the University of Georgia and a Ph.D. from Oregon State University.
Dr. Stolzenbach belongs to the American Society of Nephrology, Sigma Xi, American Association of Pharmaceutical Sciences, Drug Information Association, and the American Heart Association.
Chief Commercial Officer
Richard Marshak
Dr. Marshak brings extensive pharmaceutical experience to Nephraegis from his work across senior roles at Abbott/AbbVie, LF Consulting, and Mount Tam Biotechnologies.
While at Abbott, Dr. Marshak held roles including General Manager (GM) for Abbott’s Pain Care Franchise, GM of the US Alliance Management & Business Development team, GM of the Global Alliance Management & Commercial Assessment group, and Head of Abbott’s first Global Strategic Pricing function.
As founder of LF Consulting, Dr. Marshak has provided guidance in strategic financing, product development, and commercialization for both early and late stage biotech companies. He also has facilitated closing of multiple financial rounds for several privately held company in biotech medical nutrition.
Dr. Marshak is presently CEO of Mount Tam Biotechnologies, which is a world leader in advancing novel mTOR inhibitors across multiple indications.
Dr. Marshak received his BA and VMD degrees from the University of Pennsylvania and his MBA from the University of Chicago.